Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed unresectable primary small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), unresectable esophageal cancer, malignant pleural mesothelioma, or pleural effusions secondary to extrathoracic malignancies
• •Disease must be readily accessible to biopsy by endoscopy or percutaneous fine-needle aspiration
• •Extrathoracic metastatic disease allowed if no evidence of active intracranial or leptomeningeal metastases
• •* Patients treated with prior resection or radiotherapy for intracranial metastatic disease may be eligible provided there is no evidence of active disease on two MRIs (taken one month apart) and patients require no anticonvulsant medications or steroids to control residual symptoms
• •No limited stage SCLC or operable NSCLC
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 6 months
• •Hematopoietic:
• •Platelet count greater than 100,000/mm\^3
• •Hemoglobin greater than 10 g/dL
• •WBC greater than 3,500/mm\^3
• •Hepatic:
• •PT normal
• •Bilirubin less than 1.5 times upper limit of normal
• •Renal:
• •Creatinine no greater than 1.6 mg/dL OR
• •Creatinine clearance greater than 60 mL/min
• •Cardiovascular:
• •Any of the following conditions require clearance by a cardiologist:
• •* Prior coronary artery disease
• •* Prior transmural myocardial infarction
• •* Congestive heart failure
• •* Fixed defects on thallium scan with ejection fraction greater than 40%
• •No unstable angina
• •No recent deep venous thrombosis requiring anticoagulation
• •Pulmonary:
• •FEV1 and DLCO greater than 30% of predicted
• •pCO\_2 less than 50 mm Hg
• •pO\_2 greater than 60 mm Hg on room air
• •No recent pulmonary embolism requiring anticoagulation
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active infection
• •HIV negative
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 30 days since prior biologic therapy for the malignant tumor
• •Chemotherapy:
• •No prior decitabine
• •At least 30 days since other prior chemotherapy for the malignant tumor
• •Endocrine therapy:
• •See Disease Characteristics
• •Radiotherapy:
• •See Disease Characteristics
• •At least 30 days since prior radiotherapy for the malignant tumor (14 days for localized radiotherapy to nontarget lesions) and recovered
• •Surgery:
• •See Disease Characteristics